INTRODUCTION
Molecular imaging involves the noninvasive visualization and quantitative detection of biomolecules in vivo by means of target-specific probes (1) (2) (3) (4) (5) . Valuable applications of molecular imaging are accurate disease detection, phenotyping, and staging by gathering information on molecular pathways underlying biological and cellular processes in the diseased tissue (1) (2) (3) (4) (5) (6) . Hence, molecular imaging is likely to play a pivotal role in the stratification of patients for personalized treatment. Furthermore, molecular imaging is clinically relevant in the discovery and development of drugs and for the real-time assessment of the efficacy of drug therapy (7, 8) . Further, it can contribute to improved interventions by image-guided drug delivery and image-guided surgery (9) (10) (11) (12) . Finally, molecular imaging has an impact in the development of regenerative medicine and stemcell therapies (6) . In most molecular imaging approaches, target-specific molecular probes are engineered to enhance image contrast at the target site. These conventional targeting molecular imaging probes consist of a ligand that binds to an endogenous molecular target and an imaging label for readout. Typically, the molecular imaging probes are designed so that they can be injected intravenously for targeting biomolecules accessible via the blood circulation. For example, the active site of enzymes has been targeted with conventional probes, providing a readout for enzyme abundance (13) . However, these probes lack the possibility of detecting enzymatic activity in vivo as they are typically limited to a 1:1 probe/target binding fashion. In that respect, a new subset of protease activatable molecular imaging probes has generated considerable attention. These probes have been directed to the active site of the enzymes resulting in the cleavage and activation of the imaging probe (14) . Importantly, this will lead to signal amplification since the molecular target can continuously activate the imaging probe and, moreover, it offers a readout of enzyme activity instead of enzyme abundance. Although protease activatable probes have been mainly restricted to fluorescence optical imaging, recent progress has led to the development of protease activatable probes for photoacoustic imaging, magnetic resonance imaging (MRI), and the nuclear imaging modalities single photon emission computed tomography (SPECT) and positron emission tomography (PET) (14) (15) (16) (17) (18) . Furthermore, activatable molecular imaging probes have also successfully detected other endogenous molecular targets, such as reactive oxygen species (ROS) and metal ions. The purpose of this review is to present a general overview of the rationale behind the design of the multiple types of so-called bioresponsive molecular imaging probes for the detection of a wide range of endogenous molecular target. We will guide the reader through the emerging field of bioresponsive molecular imaging by discussing the various imaging probe strategies and their potential in vivo application per imaging modality. For optical imaging and MRI, bioresponsive probes have been reported that show signal amplification by direct activation of the imaging label (i.e. probes that go from an "off" to an "on" state) or by specific retention of the imaging probe at the site of interaction through a specific biological or chemical mechanism. Bioresponsive probes for photoacoustic imaging and SPECT/PET have been typically designed to show local retention and accumulation at the site of interaction.
BIORESPONSIVE OPTICAL PROBES: ACTI-VATION OF THE OPTICAL IMAGING LABEL

Protease sensitive bioresponsive optical probes
Proteases play crucial roles in physiology and pathology and have been identified as attractive targets for molecular imaging of a variety of diseases, including cancer, atherosclerosis, myocardial infarction, and neurological diseases (14) (15) (16) (17) (18) (19) . Multiple types of protease bioresponsive optical probes have been developed in the past decades that are specifically directed at the activity of the enzyme instead of enzyme abundance. These probes include fluorescent autoquenched probes, self-quenched or homo-fluorescence resonance energy transfer (homo-FRET) probes, dual-labeled FRET probes, fluorescent quenched activity-based probes, and luminescent probes (14) (15) (16) (17) (18) (19) .
Fluorescent autoquenched probes
An autoquenched probe typically consists of a peptide substrate linked via an amide to fluorescein/rhodamin spirolactam or spirolactone derivative, which is essentially optically silent (20) . The probe regains its fluorescence upon conversion of the amide moiety into an amine and subsequent ring-opening of the corresponding spirolactam/lactone (11, (21) (22) (23) (24) (Fig. 1) . For example, a caspase-3 and À7 autoquenched probe was designed by conjugating the peptide substrate DEVD to a rhodamine spirolactone derivative. Release of DEVD peptide by intracellular caspase-3 or À7 resulted in ring-opening of the spirolactone, followed by a strong enhancement of fluorescence (25) (Scheme 1). A γglutamyltranspeptidase autoquenched probe was successfully used for the endoscopic detection of γ-glutamyltranspeptidase in vivo in a mouse model of colon cancer (11, 26) . Recently, a novel self-immolative autoquenched probe has been described. Here, a naphthalimide dye was conjugated via an electronwithdrawing self-immolative linker to a trigger group yielding Biographies Sander van Duijnhoven earned his PhD in biomedical engineering from the Eindhoven University of Technology, The Netherlands, in 2012, where his research focused on activatable cell-penetrating imaging probes. Sander is currently pursuing a postdoctoral research training at the Radboud University Medical Center Nijmegen, The Netherlands. Furthermore, he is currently employed by Tagworks Pharmaceuticals, The Netherlands. His current research efforts focus on the development and application of targeted therapy agents and molecular imaging probes that improve therapy and/or diagnosis of disease.
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So far, these autoquenched probes use fluorophores that emit light in the visible region. Compared to visible light, near-infrared (NIR) radiation penetrates tissues more efficiently, up to several centimeters, and shows decreased absorption by natural proteins like hemoglobin (15, 28, 29) . Therefore, the development of autoquenched probes based on NIR fluorophores would be an interesting strategy to broaden the applications of these autoquenched probes in vivo.
Fluorescent self-quenched probes
Self-quenched probes or homo-FRET probes are typically macromolecular imaging probes that make use of multiple NIR fluorophores that are in close proximity to each other. When excited, the fluorophores absorb energy from each other resulting in self-quenching. The efficiency of energy transfer between the fluorophores is given by:
where r is the distance between the fluorophores and R 0 is the Förster distance (30) . The Förster distance is the distance at which the energy transfer efficiency is 50% and is typically in the range of 2-6 nm. Proteolytic activation of these probes liberates the fluorophores, resulting in the loss of homo-FRET, activating fluorescence.
Weissleder and coworkers functionalized a poly-L-lysine backbone with methoxy-terminated poly(ethylene glycol) and multiple self-quenched NIR Cy5.5 fluorophores. Degradation of the poly-L-lysine backbone by lysosomal cysteine/serine proteases resulted in liberation and activation of the fluorophores (31) (32) (33) (34) (35) . The range of applications of these macromolecular probes (~450 kDa), was extended by inclusion of various peptide substrates between the fluorophores and the backbone (Fig. 2 ). Following this approach, activatable probes were developed for a variety of enzyme targets like caspase-1, cathepsins D, E and K, HIV-1 protease, urokinase, and matrix metalloproteinases (MMPs) subtype 2 and 9 (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . For example, MMP-2 selectivity was achieved by inserting the MMP-2 sensitive peptide sequence GPLG-VRGK between the backbone and the fluorophore (44). This probe showed a threefold enhancement in NIR fluorescence signal in tumor xenografts overexpressing MMP-2, compared to tumor xenografts that were treated with an MMP inhibitor ( Fig. 2) . These self-quenched macromolecular imaging probes have been applied for in vivo protease detection in cancer, atherosclerosis, arthritis, and heart failure in rodent models . Two of these macromolecular probes, one sensitive towards MMPs (MMPSense TM ) and the other towards cathepsins (ProSense TM ), are commercially available. Recently, a series of self-quenched probes that comprise a novel architecture termed FAST TM (fluorescent activatable sensor technology) have become commercially available. In these probes, an enzyme-sensitive peptide sequence containing NIR fluorochromes at both the C and N terminus is linked to a polymer carrier at a ratio of one substrate per polymer molecule (53) . The NIR fluorophores show~95% selfquenching while the substrate is intact, but become highly fluorescent upon enzymatic cleavage of the substrate. These FAST TM self-quenched probes (~43 kDa) are significantly smaller in size compared to the macromolecular poly-L-lysine-based probes and therefore display an improved pharmacokinetic profile that enables in vivo molecular imaging at earlier time-points. These probes have successfully been used for the detection in vivo of the proteolytic activity of renin, MMPs, cathepsin B, and neutrophil elastase (52) (53) (54) (55) (56) (57) (58) (59) .
In recent years, several other activatable self-quenched fluorescent imaging probes have been developed for protease sensing. An MMP-9 sensitive liposomal system was developed that showed in vitro protease-triggered release and activation of encapsulated fluorophores in the presence of MMP-9 (60, 61) . Here, MMP-9 cleavable lipopeptides were incorporated into the liposome bilayer. Degradation of the lipopeptide resulted in destabilization of the bilayer and subsequent leakage and activation of the fluorescent dyes that were present in the lumen of the liposomes (Fig. 3 ).
Another approach of activatable self-quenched probes focussed on the protease triggered release and activation of fluorophores from a nanofiber precursor for the detection of urokinase activity (62) . The probe comprised a self-assembling peptide sequence to which a fluorophore was coupled via a urokinase-sensitive peptide moiety. Spontaneous self-assembly of the peptide probe resulted in an optically quenched nanofiber, in which the fluorophore was released and activated upon urokinase digestion in vitro. In a similar approach, a NIR triple helical peptide-based optical probe was developed. Each peptide strand was flanked by two NIR fluorescent dyes. In the triple-helical structure, the fluorescence was reduced due to quenching. In vivo studies in tumor-bearing mice showed MMP-mediated degradation of the triple-helical peptide in tumors, resulting in the local release of fluorophore labeled peptides and amplification of the fluorescent signal (63) .
Finally, self-quenched fluorophore-encapsulated nanogels have been developed that showed release and activation of the fluorophore upon nanogel degradation by hyaluronidase (64).
Fluorescent dual-labeled FRET probes
The common feature of protease-sensitive dual-labeled FRETbased molecular imaging probes is the loss of FRET between a donor fluorophore and a distinct acceptor fluorophore or nonfluorescent quencher upon enzymatic degradation of a substrate initially holding the fluorophores together. For the former class, the distance between the two distinct fluorophores, typically smaller than Förster radius (eqn 1), results in efficient FRET from the donor fluorophore to an acceptor fluorophore predominantly yielding light emission of the acceptor fluorophore. Proteolysis of the peptide substrate results in separation of the fluorophores and loss of energy transfer (Fig. 4A ). These dualwavelength probes can be used for ratiometric imaging, which provides accurate quantification of probe activation. For the second class, efficient energy transfer will take place between the donor fluorophore and a nonfluorescenct quencher, resulting in a low fluorescent signal from the donor fluorophore. Degradation of the substrate results in the dissociation of the fluorophore-quencher pair and leads to a significant enhancement in fluorescence ( Fig. 4B) . A wide variety of singlewavelength and ratiometric FRET probes has been described in literature (59, .
Genetically encoded fluorescent sensors consisting of two distinct fluorescent proteins are generally aimed at the colorimetric detection of intracellular proteases such as caspases or kinases (65, 66) . These probes typically consist of a protease cleavable substrate (65) or a conformationally responsive domain (66) sandwiched between two mutants of the green fluorescent protein (GFP) capable of FRET. Degradation of the cleavable substrate or a protease-induced conformational change of the linker domain is associated with a change in distance between the two fluorescent proteins and thus a change in FRET. For example, a genetically encoded caspase-sensitive FRET probe consisted of a cyan fluorescent protein (CFP) and a yellow fluorescent protein (YFP) joined by a peptide domain sensitive for caspase-1 or caspase-3 (65) . Proteolysis of the peptide domains significantly enhanced the distance between CFP and YFP, and resulted in a decrease in FRET. Recently, novel genetically encoded biosensors have been reported that visualize MMPs at the extracellular surface of the cell membrane (67) (68) (69) . Although recent progress led to the development of NIR fluorescent proteins enabling deep tissue imaging (96, 97) , the need for gene transfection is a strong limitation to clinical application in humans. However, it is a powerful research tool in the preclinical setting.
In other strategies, organic NIR fluorophores have been successfully employed in low molecular weight activatable FRETbased probes. For example, an MMP-7 peptide substrate was flanked with the organic Cy5.5 fluorophore and the organic NIR quencher NIRQ820 (70) . A sevenfold increase in fluorescence was observed upon incubation with MMP-7. Recent research has resulted in the development of activatable organic FRET probes specifically targeting extracellular proteases (59, (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) . One of these probes, a membrane-type MMP sensitive probe, consisting of the MMP-14 peptide substrate GRIGF-LRTAKGG and a Cy5.5/BHQ-3 NIR dye-quencher pair, was successfully used to detect MMP-14 activity in tumor-bearing mice ( Fig. 5 ) (79) . Moreover, intracellular enzymes have been effectively targeted with organic activatable FRET imaging probes (84) (85) (86) (87) (88) (89) . For example, cell-permeable caspase activatable probes were developed for the noninvasive detection of apoptosis in vivo (84) (85) (86) (87) (88) . These probes consisted of a Tat-peptide-based permeation sequence and a caspase recognition sequence (DEVD) flanked by a NIR dye-quencher pair.
A special subclass of FRET probes are the fluorescent quenched activity-based probes (ABPs) (90) . Fluorescent quenched ABPs undergo an enzyme-catalyzed chemical reaction resulting in a covalent bond between the catalytic site and the probe. This reaction is furthermore characterized by a nucleophilic displacement of the quencher group, resulting in activation of the fluorescent tag. In contrast to the classic FRET probes, the molecular target cannot continuously activate ABP probes due to the covalent bond formation. Nevertheless, cysteine cathepsin activity has successfully been detected in vivo with fluorescent quenched ABPs (91, 92) .
Apart from organic fluorophores, inorganic particles like quantum dots and gold nanoparticles have recently been exploited as donor and acceptor pairs for energy-transfer-based imaging probes (93, 94) . Gold nanoparticles demonstrated a 71% reduction of quantum dot photoluminescence, as was shown for an MMP activatable quantum-dot-based luminescent probe (95) . Quantum dots have advantages over organic fluorophores, such as strong fluorescence, higher photostability against bleaching and changes in physical environment, such as temperature and pH, and a narrow emission bandwidth (98) . Nevertheless quantum dots may have limitations for in vivo use due to potential cellular toxicity associated with Cd 2+ or Se 2À ion release from the quantum dot core (99) . Recent studies, however, indicated that potential toxicity is of minor importance for relatively small nanoparticles, such as quantum dots and chemical dots, which are efficiently cleared by the kidney's thus avoiding extensive liver and spleen uptake (100, 101) . Specifically, quantum dots with a hydrodynamic diameter smaller than 5.5 nm showed efficient renal excretion (101) .
Recently, the principles of FRET imaging and photodynamic therapy (PDT) have been combined into the development of enzyme activatable photodynamic molecular beacons (102) (103) (104) (105) (106) . In photodynamic therapy (PDT), the cytotoxic agent 1 O 2 is generated by light activation of a photosensitizer in the presence of oxygen (107) . Furthermore, NIR light emission from the photosensitizer is typically observed. Activatable photodynamic molecular beacons have been developed for MMP-7, caspase 3, and fibroblast activation protein, by flanking enzyme-specific substrates with a photosensitizer and a fluorescence/ 1 O 2 quencher (103-106). NIR fluorescence imaging of a MMP-7 sensitive photodynamic molecular beacon showed tumor-specific activation in vivo, suggesting tumor-specific delivery of the photosensitizer, which potentially will contribute to improved tumor-specific photodynamic therapy (103).
Bioresponsive luminescent probes
Bioluminescence is typically observed upon enzymatic oxidation of specific substrates by luciferases (108) . In bioluminescence imaging, the light production does not rely on external excitation, and therefore background signals due to tissue autofluorescence are not present. Luminescent activatable probes, known as caged luciferase substrates, combine the production of bioluminescence by luciferases with the enzymatic activity of other proteases. In these probes, D-luciferin, the substrate for luciferase, is typically protected by a specific enzymatic trigger (Scheme 2). The presence of the enzymatic trigger prevents the enzymatic oxidation of the probe by luciferase. However, upon enzymatic digestion of the trigger, D-luciferin is released and will produce a bioluminescent signal once consumed by luciferase. In vivo, luminescent activatable probes have successfully been employed to visualize a variety of enzymes, including β-galactosidase (reporter enzyme), β-lactamase, caspase, and furin (109) (110) (111) (112) . A recent study demonstrated that D-cysteine and 2-cyanobenzothiazoles (CBT) selectively react with each other in vivo to yield D-luciferin (113) . A bioresponsive luminescent probe was developed by conjugating D-cysteine to a caspase 3/7 substrate. In vivo release of D-luciferin from the caspase 3/7 sensitive probe in luciferase-expressing tumor-bearing mice allowed the reaction with administered 6-amino-CBT to form 6-amino-D-luciferin. Subsequently reaction of 6-amino-D-luciferin with luciferase yielded a bioluminescent signal (113) . Similar to fluorescent genetically encoded FRET probes, activatable luminescent probes are valuable for preclinical studies, but clinical translation is restricted due to the need for gene transfection of the luciferase gene. Interestingly, a recent study has demonstrated that it may become possible to enlist endogenous enzymes from nonluminescent organisms such as luciferases, circumventing the need for genetic manipulation (114).
pH-sensitive optical probes
The important role of intracellular pH in cell, enzyme, and tissue activity as well as the recognition that the tumor's extracellular microenvironment is relatively acidic compared to normal tissue has stimulated the development of pH-sensitive fluorescent imaging probes (115) (116) (117) (118) (119) (120) (121) (122) (123) (124) (125) (126) (127) (128) (129) . On average, the pH in the tumor microenvironment is between 6 and 7 (130) . In the early days, pHdependent probes were aimed at the enhancement of fluorescence of the GFP upon a decrease in pH (110) . Other strategies focussing on pH-dependent activation of the fluorescent imaging label used pH-sensitive nanoparticles, for example, liposomes or polypeptides that showed release and activation of fluorescence of self-quenched fluorophores at low pH (119) (120) (121) . More recently, low molecular weight pH-sensitive autoquenched fluorescent probes have been developed ( Fig. 6 ). Most of these probes are specifically targeted to tumors and become fluorescent once accumulated in acidic lysosomes, typically having a pH varying from 4 to 6 (122) (123) (124) (125) (126) (127) (128) . For example, a near-infrared pH-activatable fluorophore conjugated to a RGD-peptide was successfully used for the targeting of α v β 3 integrin-expressing tumors (124) . Subsequent α v β 3 integrin-mediated internalization of the probe into acidic lysosomes resulted in an enhancement of fluorescence. Recently, a self-assembled self-quenched imaging probe has been developed that showed efficient disassembly and activation of fluorescence at pH < 7.0 (129).
Optical probes activated by reactive oxygen/nitrogen species
Reactive oxygen species and reactive nitrogen species (RNS) play a crucial role in maintaining normal physiology. However, excessive production of ROS/RNS has been associated with a variety of pathological diseases, such as cancer and cardiovascular disease (131, 132) . Activatable fluorescent imaging probes for ROS/RNS detection are mainly based on autoquenched probes in which a fluorophore is coupled to a ROS/RNS trigger, resulting in a nonfluorescent molecule (20, 133) . Reaction of these probes with ROS/RNS results in the activation of the fluorescent moiety (Scheme 3). This approach has been extensively exploited, resulting in activatable fluorescent probes for a range of ROS/RNS, including hydrogen peroxide (
nitric oxide (NO) (150) (151) (152) , hypochlorous acid (HOCl) (142) (143) (144) (153) (154) (155) , and hydroxyl radical (·OH) (144, 156) . Other imaging approaches have focussed on the colorimetric detection of ROS/RNS (157) (158) (159) (160) or used genetically encoded biosensors (161) (162) (163) . ROS/RNS imaging methods have been applied in cell-culture experiments in vitro, but strategies to visualize ROS/RNS in vivo have been limited (142, (164) (165) (166) (167) . The first in vivo study employed nanoparticles formulated from peroxalate esters and fluorescent dyes (164) . Reaction of the peroxalate esters with H 2 O 2 resulted in high-energy dioxetanedione intermediates that subsequently facilitated excitation of the encapsulated dye. This probe was used to detect H 2 O 2 in the peritoneal cavity of mice during a lipopolysaccharide-induced inflammatory response. H 2 O 2 production was also visualized in tumor-bearing mice using a peroxy-caged luciferin-1 bioluminescent probe (165) . Selective reaction of this probe with H 2 O 2 released firefly luciferin that subsequently was converted to a bioluminescent active moiety by firefly luciferase. This probe was studied in luciferase-expressing tumor-bearing mice and showed tumorspecific activation. In a follow-up study, a dual-analyte bioluminescent strategy was developed for the simultaneous detection of H 2 O 2 and caspase (166) . In this approach, two complementary bioorthogonal caged precursors (6-hydroxy-2cyanobenzothiazole (HCBT) and D-cysteine) were unmasked by, respectively, H 2 O 2 and caspase 8. After their release, the HCBT and D-cysteine cages react with one another and form luciferin, producing a bioluminescent signal upon reaction with luciferase. An in vivo study in a luciferase-expressing mouse model of inflammation demonstrated proof-of-concept for this dual-analyte detection technology (166) . Panizzi et al. developed a ROS/RNS nanoparticle to which quenched oxazine reporters were conjugated (142) . Release of the oxazine reporters by ROS/RNS interaction, in particular ONOO À and HOCl, resulted in restoration of its fluorescence. This nanoparticle was studied in a mouse model of myocardial infarction and showed enhancement of oxazine fluorescence in the infarcted areas of the heart. Lastly, a H 2 O 2 ratiometric FRET probe has recently been developed employing fluorescein and Cy-5 as a donor/acceptor FRET pair (167) . Reaction of this probe with H 2 O 2 led to a decrease in FRET and subsequent increase in fluorescein fluorescence, as was demonstrated in vitro and in vivo in a mouse model of lung inflammation.
Optical probes activated upon target binding
The final class of bioresponsive fluorescent imaging probes shows a change in FRET between a donor fluorophore and acceptor fluorophore or quencher upon target binding. For instance, various genetically encoded FRET sensors based on GFP-mutants undergo a conformational change upon target binding and allowed the in vitro ratiometric detection of, for example ATP, glucose, and metal ions like calcium, zinc, and cadmium (168) (169) (170) (171) (172) . Another strategy is focussed on FRET oligonucleic acid-based aptamer probes in which a fluorescent label is efficiently activated upon a conformational change of the probe induced by binding to a biomarker ( Fig. 7) (173, 174) . Alternatively, micellar and liposomal formulations containing high concentrations of self-quenched fluorescent dyes have been developed that destabilize and release the fluorescent dyes upon target binding, cellular internalization, and subsequent nanocarrier degradation (175, 176) . Similarly, various FRET probes have been developed that upon target binding and subsequent cellular internalization showed activation of the optical imaging label (177-179).
Fluorescence lifetime imaging
For most fluorescence techniques, the increased fluorescence intensity upon activation of the optical imaging probe is used as a measure of activation. Next to fluorescence intensity, the fluorescence lifetime (FLT) properties of the fluorophores change due to activation of the probe (180) . The fluorescence lifetime describes the length of time between the excitation of a fluorophore and subsequent fluorescent emission and can be influenced by changes in the environment. For example, energy transfer between the donor and acceptor fluorophore in FRETbased imaging probes results in a lower quantum yield as well as decrease of the fluorescence lifetime of the donor fluorophore (181) . Upon probe activation, the quantum yield and lifetime are restored, resulting in an increase in fluorescence intensity and lifetime of the donor fluorophore. Consequently, monitoring the fluorescence lifetime can be utilized to assess whether in vivo probe activation has occurred (182).
Clinical application of optical imaging probes
The previous paragraphs present an overview of bioresponsive optical imaging probes. A unique feature of optical imaging is that the imaging probes can be turned on upon activation by a specific endogenous molecular target, allowing high target-tobackground ratios compared to conventional targeting probes. Unfortunately, the limited depth of light penetration through human tissue hampers the application of optical imaging probes for image-based whole-body diagnostics in vivo. However, in recent years these probes have been demonstrated to have a high potential in intraoperative imaging approaches of surfacelocated tissues, such as those encountered during endoscopic or optically guided surgical interventions (6, (10) (11) (12) (183) (184) (185) . A first study in a human showed the efficacy of a folate receptorα targeting non-NIR fluorescence imaging probe for imageguided tumor margin detection during cancer surgery (186) . This study and various other studies provide essential proof-ofprinciple that intraoperative optical imaging holds great promise to become a standard clinical tool in cancer treatment (186) (187) (188) (189) (190) (191) (192) (193) (194) (195) (196) (197) . While the pioneering studies in a human employed targeted optical imaging probes, multiple bioresponsive optical imaging probes are currently also in the process of obtaining regulatory approval for clinical proof-of-principle studies (198) .
BIORESPONSIVE PHOTOACOUSTIC IMAGING PROBES
It has been shown recently that NIR fluorophores can also be used for photoacoustic tomography (PAT) (199) . This technique, which is one of fastest growing imaging modalities in recent years (200) , is based on the monitoring of ultrasonic signals generated in response to light absorption properties of specific endogenous molecules, such as hemoglobin or exogenously administered imaging probes. In more detail, photoabsorbing molecules absorb light from nonionizing laser pulses, resulting in subsequent energy dissipation as heat. This process subsequently leads to thermal expansion and emission of broadband acoustic waves. The ultrasonic waves can be detected with adequate ultrasonic transducers, up to several centimeters in large animals and humans (15) . The signal is subsequently processed with reconstruction algorithms to recover the initial absorbed energy distribution. Thus, photoacoustic imaging is a hybrid technique making use of optical absorption and ultrasonic wave propagation. Thereby, photoacoustic imaging combines the advantages of both techniques: the high contrast of optical imaging and the high resolution of ultrasonic imaging, which offers great promise for this novel imaging modality in future clinical applications (15) . An optimal photoacoustic imaging probe is characterized by a high extinction coefficient that furthermore possesses efficient conversion of the electromagnetic energy into mechanical energy. Despite NIR fluorescent dyes that do show fluorescence, these chromophores have been proven to be attractive for photoacoustic imaging because of their relatively low quantum yield. Therefore, a major part of the absorbed energy, more than 80%, is transferred to optoacoustic signals (201) . Furthermore, the specific use of NIR chromophores as photoacoustic imaging agents in combination with excitation light of a corresponding wavelength allows background signal suppression, because of the low absorbance of endogenous photoabsorbers present in normal tissue in the NIR wavelength window (15) . In recent years, several bioresponsive photoacoustic imaging probes have been developed. Razansky et al. explored the use of MMPSense TM 680 for multispectral photoacoustic imaging (201) . They demonstrated that the chromophores in MMPSense TM 680 show an absorption change upon enzymatic activation, which could be detected by multispectral photoacoustic imaging at 635 and 675 nm. This approach allowed high accurate three-dimensional photoacoustic imaging of MMP activity in human carotid plaques (201) . In other work, Levi et al. developed an MMP activatable cell-penetrating peptide labeled with two chromophores, BHQ3 and Alexa750, which show photoacoustic signals upon laser irradiation at 675 and 750 nm respectively (202) . It was demonstrated that activation of the imaging probe in vitro resulted in efficient cellular uptake of the cell-penetrating peptide domain labeled with BHQ3, while the counterpart containing Alexa750 diffused away, as was confirmed by photoacoustic signal intensity of both chromophores (202) . This probe was subsequently explored in vivo and multispectral photoacoustic imaging was used to detect tumorassociated MMP activity in mice (203) . In another study, ratiometric multispectral photoacoustic imaging using an activatable imaging nanoprobe was successfully demonstrated for detection of cancer-associated MMP activity in vivo (204) . The nanoprobe consisted of multiple chromophores BHQ-3 that were conjugated via MMP cleavable linkers to copper sulfide nanoparticles. Both BHQ-3 and the copper sulfide nanoparticles, which exhibit distinctive absorption peaks at 680 nm and 930 nm respectively, generate optoacoustic signals upon laser radiation. Activation of this nanoprobe by tumor-associated MMPs resulted in the release and tumor wash-out of the small molecular weight BHQ-3 molecules, while the large CuS nanoparticles were retained for much longer in the tumor. Multispectral photoacoustic imaging of the signal ratio 680 nm/930 nm consequently showed a decrease in ratio in tumor tissue in vivo and demonstrated the use of this probe for proteinase activity detection in vivo (204) . Lastly, novel activatable photoacoustic probes have been developed for photoacoustic lifetime imaging (205) (206) (207) . In one strategy, a protease sensitive imaging probe has been proposed that contains self-assembled methylene blue chromophores. Upon enzymatic activation, the chromophore monomers will be released, which will result in a change in the excited state lifetime of the chromophore (205) . The same chromophores demonstrated pO 2 dependent relaxation (206) . A follow-up study proved that these chromophores could be used for photoacoustic lifetime imaging of hypoxia in vivo in tumor-bearing mice (207) . In summary, photoacoustic imaging is one of the youngest members of the molecular imaging community. It is foreseen as a future noninvasive clinical tool for accurate detection and characterization of, for example, carotid plaques in patients (201) and is characterized by an exceptional improved imaging depth compared to optical imaging. Furthermore, photoacoustic imaging can be easily combined with traditional ultrasound, which will provide anatomic, functional, and molecular information with a single image (15).
BIORESPONSIVE MRI PROBES: ACTIVATION OF THE MRI CONTRAST AGENT
In contrast to optical imaging, MRI can be employed for wholebody diagnostic imaging in humans. MRI presents an attractive platform for molecular imaging due to the conjunction of highresolution anatomical imaging and mapping of the activity of specific biomarkers by MRI contrast agents. Unlike optical or radiolabeled molecular imaging probes, MRI contrast agents, such as gadolinium chelates, do not directly generate a signal but are detected through their ability to shorten the water proton relaxation times, that is, the longitudinal (spin-lattice) and transverse (spin-spin) relaxation times (T 1 and T 2 , respectively) (208) . In a T 1 -weighted MRI image, T 1 -shortening results in positive contrast (bright spots), whereas in a T 2 -weighted image, T 2 -shortening generates negative contrast (dark areas). The longitudinal relaxivity (r 1 ) of a contrast agent is modulated by several parameters (209, 210) , including the number of inner sphere water molecules directly coordinated to paramagnetic complex (q), τ m the exchange rate of the metal-coordinated water molecule with the bulk water, and τ R the rotational correlation time of the contrast agent ( Fig. 8 ). Smart MRI contrast agents have been developed that show a change in one of these parameters upon activation due to a biochemical stimulus leading typically to an increase in r 1 . Typically, these MRI contrast agents go from an "off" state, with a minimal effect on T 1 /T 2 , to an "on" state, with a large effect on T 1 /T 2 shortening (17, 210, 211) . In the next paragraphs, we will present an overview of MRI imaging probes that generate a change in contrast as a result of activation of the MRI contrast agent. Interestingly, during the preparation of this manuscript, an in-depth review specifically focussed on responsive MRI probes has been reported (212).
Bioresponsive T 1 -weighted MRI contrast agents
Longitudinal relaxivity enhancement via modulation of water coordination sites
Several strategies have been explored to enhance the longitudinal relaxivity of paramagnetic gadolinium complexes after its activation due to an increase in the number of water molecules directly coordinated to the metal centre (Scheme 4). The first enzymatic activatable agent has been reported by Meade and coworkers (213, 214) , in which the water coordination site of gadolinium complex was blocked with a galactopyranosyl ring reducing "q" (q << 1). Its enzymatic cleavage by the reporter enzyme β-galactosidase restores the water coordination site (q = 1) leading to an efficient T 1 -shortening. Another class of gadolinium-based agents can interact with endogenous metal ions, such as Ca 2+ and Zn 2+ , resulting in an increase in water coordination sites and thus improved longitudinal relaxivity (215, 216) . A third class of activatable MRI contrast agents uses pH-responsive gadolinium chelates that display relaxation enhancement at acidic conditions (217) (218) (219) . Finally, a recent class used redox responsive gadolinium chelates, for which q does increase upon reaction with NADH (220). Despite the development of various bioresponsive MR imaging probes of this class (213) (214) (215) (216) (217) (218) (219) (220) , exploration in vivo has been limited (221) . A cellpermeable Zn 2+ sensing MR imaging probe showed the detection of elevated Zn 2+ levels in the hippocampus in rats (221) . Importantly, intracranial injection of the imaging probe was performed to obtain sufficient imaging probe concentration in the brain. Typically, the exogenous imaging probe concentration at the target site should be >1 uM because of the relatively low sensitivity of MRI, which requires relative high biomarker concentrations (212) . Furthermore, there is a need for efficient cellular transport of most of these agents to reach their intracellular targets. Therefore, to apply these probes in vivo may be challenging, especially in case of intravenous injection, and may limit clinical translation.
Reducing the water mobility can modulate changes in the longitudinal relaxivity of the protons of water molecules. For example, pH-sensitive micelles and liposomes have been reported containing gadolinium-based complexes in its aqueous lumen (222) (223) (224) , which have a low effect on the longitudinal relaxivity of the protons of the bulk water molecules due to the limited transmembrane water exchange rate. At low pH, the contrast agents are released and a strong increase in the longitudinal relaxivity is observed. In another approach, gadolinium chelates were efficiently quenched by encapsulation in the polymer coating of a superparamagnetic iron oxide particle (225) . In acidic environments the Gd chelates were efficiently released with a subsequent increase in longitudinal relaxation rate.
Relaxivity enhancement via modulation of rotational correlation time
T 1 -shortening of the protons of water molecules can be achieved by slowing down the molecular tumbling rate of the paramagnetic complex (1/τ R ) (226) . Nivorozhkin and coworkers have developed a carboxypeptidase B activatable MRI contrast agent that gained affinity for the high molecular weight protein albumin upon activation, resulting in a reduced tumbling rate and therefore higher relaxivity (227) . In similar approaches, activatable albumin/protein-binding Gd-based MRI contrast agents have been developed for the detection of reporter enzyme β-galactosidase, carbonic anhydrase, and zinc in vitro (228) (229) (230) (231) . In another approach, Gd-based MRI contrast agents showed polymerization upon specific activation by myeloperoxidase (MPO), resulting in a slower tumbling rate and therefore in an enhancement of the longitudinal relaxivity (232-236) (Fig. 9 ). In this approach, Gd-labeled phenol derivatives are oxidized by MPO, resulting in tyrosyl radicals, which will form dityrosine cross-links. Using this approach, MPO activity was visualized in a mouse model of myocardial infarction in vivo (233).
Bioresponsive T 2 -weighted MRI contrast agents
Superparamagnetic iron oxide (SPIO) nanoparticles are widely used as T 2 -weighted MRI contrast agents. Recently, it has been shown that clusters of SPIOs display faster T 2 relaxation properties of the individual iron oxide cores compared to the nonclustered iron oxide cores. Furthermore, clustering results in an increased concentration of the MRI contrast agent and, therefore, both processes contribute to an enhanced transverse relaxivity (237) . Activatable SPIOs have been developed that cluster upon activation by MPO. In this approach, dopamine was attached to the surface of the SPIOs. In the presence of MPO and H 2 O 2 , this phenol derivative is transformed into a tyrosyl radical that causes dityrosine cross-links between the nanoparticles (238) . In another strategy, biotin and neutravidin coated SPIOs were shielded with polyethylene glycol (PEG) that could be proteolytically removed by MMP-2 to initiate self-assembly (239,240) ( Fig. 10) . In a related approach, Schellenberger et al. designed iron oxide particles sterically stabilized by PEG that showed significant aggregation by interparticle electrostatic and magnetic attraction upon MMP-9induced dePEGylation (241) . Finally, Atanasijevic et al. reported
on SPIOs that were functionalized with calmodulin, a Ca 2+ sensing protein, and showed Ca 2+ -dependent protein-protein interaction driving particle clustering (242) . In contrast to the clustering of SPIOs, several iron-oxide-based imaging probes have been developed that show disassembly upon probe activation, resulting in a loss of relaxivity enhancement. In these disassembly approaches the individual iron oxide particles are connected to each other by cleavable linkers. Following this strategy, probes has been developed for the sensing of caspase-3, MMP-2, and endonucleases in vitro in experimental settings (243) (244) (245) . The fact that enzyme activation results in loss of relaxivity enhancement challenges applications of this approach for imaging in vivo.
In another strategy (246) , iron oxides were encapsulated in a polymer coating restricting the interaction of the iron oxide core with surrounding water. In vitro enzymatic degradation of the dextran coating by dextranase resulted in a strong T 2 shortening.
Bioresponsive paramagnetic CEST MRI agents
Another class of activatable paramagnetic MRI contrast agents induces MR contrast enhancement utilizing chemical exchange saturation transfer (CEST) (17, 247) . Typically, these CEST MRI contrast agents consist of lanthamide complexes containing exchangeable water protons with a large chemical shift compared to the bulk water protons. Upon irradiation of these exchangeable water protons using a selective radiofrequency pulse, the intensity of the bulk water signal is reduced via chemical exchange saturation transfer. Bioresponsive paramagnetic CEST agents have been designed that display a change in the CEST effect upon interaction with a biochemical stimulus (17, 247) . For instance, Pagel and coworkers reported on a paramagnetic CEST agent that showed urokinase plasminogen activator (uPA) specific degradation, whereby an amide was cleaved and transformed into an amine, which caused disappearance of CEST (248) (Fig. 11) . In another approach, a redox sensitive CEST agent was developed that could switch between paramagnetic Co(II) wileyonlinelibrary.com/journal/cmmi with a high CEST signal to a diamagnetic Co(III) state with a low CEST signal (249) . Oxidation of the CEST agent resulted in Co(III) and a reduction in CEST signal, as was demonstrated in vitro (249) . Various other bioresponsive CEST agents have been developed to monitor pH differences, redox status, ROS, metabolites, enzymes, and minerals (250) (251) (252) (253) (254) (255) (256) (257) (258) (259) (260) (261) (262) . Most of these probes have been limited to validation in vitro, while studies in vivo are needed to reveal potential clinical translation. A particular challenge may be to obtain sufficient concentration of imaging probes at the target site, especially in the case of intracellular targets. Importantly, two recent papers have explored the use of bioresponsive CEST agents in vivo (248, 263) . First, an uPA sensitive CEST agent, which showed disappearance of CEST upon activation, was used to detect uPA in tumor-bearing mice (248) . The other preclinical study was performed with a hypoxiasensitive CEST agent (263) . This CEST agent contained two paramagnetic nitroxide free radical groups that quenched the CEST signal due to rapid T 1 relaxation of water by the nitroxide unpaired electrons. Upon reduction to bis(hydroxylamine) in hypoxic areas, the T 1 relaxation is restored and the CEST signal is activated. Reduction of this probe in vivo was successfully detected and warrants further research in preclinical models of disease (263) . A general drawback for all the above activatable MRI contrast agents is the need for a pre-and post-MRI scan to calculate contrast changes by subtraction of the two images, which requires strict image registration to prevent any artefact. This is especially challenging if probe activation takes time and one scan session is not enough. Furthermore, any morphological changes between scans (e.g. tumor shrinkage due to therapy) strongly hampers correct image subtraction and final interpretation.
Bioresponsive hyperpolarized MR agents
A final class of activatable MR contrast agents are hyperpolarized probes useful for imaging of metabolic pathways (264) . Hyperpolarization of the probe results in a significant redistribution of the populations of nuclear spins in a magnetic field, leading to a signal increase by a factor of 10,000 or more. Whereas the concentration of endogenous metabolites is below the detection threshold of MRI, hyperpolarized metabolic molecules can be detected and are widely used to study changes in cancerassociated metabolic pathways (264) . Importantly, the relaxation of the hyperpolarized agents will be determined by the T 1 relaxation time. For that reason, typical long-life T 1 atoms such as 13 C (>20 s half-life) are best-suited for this technology. Multipe 13 C metabolic agents have been developed and investigated in vitro and/or in vivo, such as 13 C-hyperpolarized lactate, pyruvate, fructose, and glutamine (264) (265) (266) . For example, hyperpolarized [5-13 C] glutamine was used to study glutaminase activity in vivo in liver cancer metabolism in rats (265) . Very recently, a first study in a human was successfully performed with hyperpolarized [1-13 C]pyruvate to characterize tumor metabolism in prostate cancer, indicating that clinical translation of this technology is feasible (266).
BIORESPONSIVE PROBES FACILITATING SITE-SPECIFIC RETENTION OF THE IMAGING LABEL
Activation of autoquenched, self-quenched, and FRET optical probes results in the transition of a fluorophore from an "off" state to an "on" state or FRET between a donor and acceptor fluorophore. For the imaging probes that are activated by extracellular proteases, for example MMPs, the fluorophores may diffuse away from the cleavage site, resulting in lower signal-tobackground ratios (267) . Similarly, activatable MRI contrast agents might show wash-out after activation, except for the activatable SPIOs. In order to avoid wash-out, a special class of activatable probes has been developed in which the fluorescent or MRI imaging label is not activated, but probe activation leads to retention of the imaging probe at the activation site, thereby accumulating the imaging label in the target tissue and thus increasing signal. Importantly, these types of imaging probes are not limited to one specific imaging modality. Therefore, this approach led to the successful development of bioresponsive nuclear imaging probes. In the following paragraphs the different approaches to achieve specific retention of the imaging label will be addressed. First, probes will be discussed that require the presence of a specific target for activation and are not amendable to the detection of other targets. Thereafter, activatable molecular imaging probes will be discussed where retention can be modulated by a wider variety of targets by including different substrates/triggers.
Bioresponsive accumulating probes lacking tuning possibilities for novel targets
In this section, activatable imaging probes will be discussed that show retention and accumulation of the imaging label upon activation. All these probes are designed to be specifically activated by a unique biomarker (e.g. specific enzyme, pH, hypoxic tissue) and typically lack the possibility to be adapted to a wide variety of targets.
Bioresponsive accumulating probes restricted to specific enzymes
An example of an activatable imaging probe that has a narrow target-application range has been developed by the group of Ruoslahti (268, 269) . In their work, fluorescent probes have been developed that specifically penetrate integrin and neuropilin overexpressing cells upon proteolytic activation. These probes were successfully targeted to tumors through a three-step process: first an RGD-peptide motif mediated binding to integrins on tumor endothelium. Subsequent proteolytic degradation of the probe exposed a C-terminal R/KXXR/K motif, which mediated neuropilin-1-dependent cellular penetration (269) .
In another approach, fluorescent, MRI, and radiolabeled probe analogs were developed displaying specific cross-linking to thrombi by the activity of transglutaminase FXIIIa (270) (271) (272) (273) (274) . In a mouse model of myocardial infarction, transglutaminase FXIIIa activity was successfully detected using a radiolabeled analog (273, 274) . Redesigning this probe to achieve cross-linking upon interaction with other enzymatic targets, such as MMPs, that do not show transglutaminase activity is cumbersome. Therefore this type of imaging probe cannot be adapted to detect a wide range of other targets. Recently, another MRI activatable probe was developed that upon activation binds efficiently to fibrin in fresh thrombi (275) . The probe is based on a low-affinity fibrinbinding linear peptide that becomes cyclic by the activity of protein disulfide isomerase. Upon cyclization of the imaging probe, the probe showed strongly enhanced fibrin binding. Because protein disulfide isomerase is only present on activated platelets the activated MRI imaging probe predominantly bound to fresh thrombi in vitro. Furthermore, a metalloporphyrin MRI imaging probe was developed that became insoluble after cleavage of phosphate end-groups by the reporter enzyme secreted alkaline phosphatase (276) . This probe showed strong accumulation and T 1 shortening in vivo in the vicinity of the areas expressing the reporter enzyme.
Intracellular enzymatic targets have been successfully targeted with radiolabeled probes showing increased retention upon enzymatic activation. Intensive research over many decades has resulted in various 18 F activatable PET probes that are intracellularly phosphorylated and subsequently trapped. A well-known example is the clinically applied PET imaging probe 18 F-fluorodeoxyglucose (FDG) that is used for imaging of glucose metabolism (277) . Cancerous tissue typically has a high metabolic activity characterized by an increased uptake of glucose/FDG. Subsequently, the elevated intracellular activity of the enzyme hexokinase enables efficient phosphorylation of FDG, resulting in cellular entrapment and subsequent accumulation of the radiolabeled probe (Scheme 5) as further downstream probe metabolism is blocked. Other phosphorylation sensitive PET imaging probes have been developed for the imaging of cell proliferation: 18 F-fluoro-3′-deoxy-3′-L-fluorothymidine (FLT) and (248) . The horizontal reaction shows MR saturation of the amide proton (in red), followed by CEST, which transfers the MR saturation to water and decreases the water signal. The vertical reaction shows cleavage of the ZGGR peptide by uPA, which results in the conversion of the amide to an amine that does not generate CEST. (B) The uPA sensitive CEST probe showed CEST in the absence of uPA but not after cleavage by uPA. Figure is reprinted (adapted) with permission from (248) . 18 F-choline (278) (279) (280) . FLT is a thymidine analog that is incorporated into the DNA of proliferative cells, such as those found in tumor tissue. Once FLT is taken up by cells and phosphorylated by thymidine kinase 1, it becomes trapped intracellularly (278) . 18 F-choline is incorporated in the membrane of cancer cells that show increased lipid synthesis during tumor cell growth (279, 280) . Specifically, choline is phosphorylated by choline kinase and subsequently built into the cell membrane as phosphatidylcholine. Both FLT and 18 F-choline are clinically used for imaging of different types of proliferating cancers in patients (280, 281) . Recently, an advanced H 2 O 2 activatable FLT probe was developed for ROS detection in proliferative cells (282) . Validation of this probe in vivo is expected and such a probe may be valuable for detection of ROS-producing cancers. Another paper described a dual-strategy for imaging of secondary Cerenkov induced fluorescence using both FDG and an MMP-sensitive fluorescein-quencher optical probe (283) . Local FDG nuclear radiation will result in Cerenkov radiation, which can be absorbed by the fluorescein-containing optical probe. In case fluorescein is activated and released by MMP, absorption of Cerenkov radiation will result in a fluorescent signal. It was demonstrated that this probe can detect concomitant enzyme and glycolytic activity in vivo (283) . Another intracellular target that can phosphorylate radiolabeled probes, leading to cellular probe accumulation, is herpes simplex virus-1 thymidine kinase (284) . In this approach, a probe, for example FIAU (1-(2'-deoxy-2'-fluoro-1-β-Darabinofuranosyl)-5-iodouracil is used, which resembles the nucleotide uridine. In contrast to mammalian thymidine kinase, the herpex simplex virus-1 thymidine kinase (HSV1-TK) is less discriminative and is able to phosphorylate these probes, leading to trapping and accumulation in cells expressing HSV1-TK. This enzyme is extensively used in reporter gene imaging approaches using PET or SPECT as a research tool (284, 285) , but has also clinically been tested in glioma imaging (286) as well as in combination with ganciclovir in enzyme/prodrug therapy of gliomas (287) . Zhang et al. developed a FRET imaging probe for the detection of Bruton's tyrosine kinase in live cells (288) . Reaction of the imaging probe with kinase resulted in removal and cellular washout of the quencher and activation and retention of the optical imaging label.
Next to kinases, other intracellular enzymes such as caspases, indicative for apoptosis, have been targeted with activatable imaging probes resulting in enhanced retention. For example, radiolabeled cell-penetrating caspase substrates were developed for SPECT imaging and showed enhanced retention in apoptotic cells in vitro (289) and in tumors in vivo (290) .
Finally, dynamic changes in glycosylation, the posttranslational modification of proteins, are associated with tumor progression (291) . Therefore, imaging strategies have been explored to image tissue glycosylation in vivo (292, 293) . In these strategies, bioresponsive sugar analogues containing a bioorthogonal functional group (e.g. azide) are metabolized and incorporated into cell-surface glycans. The azide can subsequently react with imaging probes bearing a complementary bioorthogonal functional group. This technique was demonstrated in zebrafish (294) , but translation to rodents to specifically visualize tumor tissue has proven challenging, as the azidosugars are metabolized and incorporated into glycans in various tissues (291) . Therefore, Xie et al. employed targeted liposomes to deliver the bioresponsive azidosugars specifically to the tumor tissue. Tumor glycan-specific incorporation of the azidosugars in vivo was demonstrated using a bioorthogonal optical imaging probe (291).
Bioresponsive probes accumulating in acidic tissues
Differences in pH between diseased and healthy tissue have been used to mediate the retention of imaging probes in diseased tissues. For example, an electrostatically quenched cell-penetrating micelle was selectively activated at the lower extracellular pH of the tumor microenvironment (on average pH is between 6 and 7 (130)), resulting in intracellular accumulation and release of a model drug (295). This model system may also be used to release and activate optical imaging probes ( Fig. 12 ). An alternative approach is aimed at the local release and accumulation of iron-oxide particles from pH-responsive polymeric micelles at acidic conditions (296) . This activatable T 2 MRI contrast agent was used for the detection of ischemic areas in the brain of rats. Furthermore, pH-dependent cell-membrane insertion peptides containing either a fluorescent or a radioactive imaging label were developed and showed efficient membrane tagging and specific retention in acidic tumor tissues (297, 298) .
Bioresponsive probes accumulating in hypoxic tissues
Over the past decades, much research has been devoted to the development of imaging probes for detection of hypoxic areas, often encountered in tumors that grow beyond the region reached by vascular oxygen (299, 300) . The first probes were based on radiolabeled 2-nitroimidazoles. After cellular entry via diffusion, the 2-nitroimidazole moiety undergoes an enzymemediated single-electron reduction to produce reactive oxygen radical anions. In normoxic tissues, the radical anion is rapidly back-oxidized to the original compound and eventually diffuses out of the cells and tissues. In hypoxic tissues, however, the radical anion may be further reduced and subsequently will be trapped in cells via covalent binding to the macromolecular components (301) . A PET imaging probe, 18 F-fluoromisonidazole (FMISO), has been administered in patients and demonstrated to be a valuable tool for the evaluation of tumor response during and after fractionated radiation therapy (302) . Second-and third-generation 2-nitroimidazole probes ( 18 F-fluoroazomycin arabinoside (FAZA) and 18 F-flortanidazole (HX4)) have also shown promising in vivo results in patients with head and neck cancer (303) (304) (305) . Another well-studied probe is 64 Cu-diacetylbis(N 4 -methylthiosemicarbazonate), Cu-ATSM. Upon cellular uptake, Cu(II)-ATSM is reduced to an unstable Cu(I)-ATSM probe, followed by dissociation of the metal complex and subsequent irreversible trapping of Cu(I) within the cell (306) . While other processes such as copper metabolism may play a role in Cu-ATSM tumor uptake, this probe showed clinical value for patient diagnostics (299, 306, 307) . Furthermore, other hypoxic imaging probes have recently been developed. A 4-nitrobenzylester-containing 99m Tc-probe showed efficient reduction to a cell-membrane impermeable carboxylate anion with consequent cellular retention in vitro (308) . Finally, a radiolabeled-peptide-based probe was developed that was degraded and retained in hypoxia-inducible factor-1 active tumor regions in vivo (309).
Bioresponsive accumulating probes enabling tuning for target specificity
In this section, bioresponsive accumulating molecular imaging probes will be discussed that can be applied for the detection of a wide variety of targets. A first class of probes exhibit hydrophobic clustering upon proteolytic removal of a hydrophilic component, thereby decreasing the in vivo clearance rate from the target tissue (310-312) (Fig. 13 ). These probes showed good promise for the detection of MMP-2 and MMP-7 in vivo, employing MRI T 1 -contrast agents as imaging labels (310) (311) (312) . Recently, this concept was further developed for PET purposes. Hereto, an 18 F-labeled hydrophobic tetramethylrhodamine moiety was conjugated to a hydrophilic PEG linker by an MMP-2 cleavable substrate (313) .
A second imaging concept was proposed by Tsien and coworkers. They reported on activatable cell-penetrating peptide (ACPP) imaging probes functionalized with fluorophores or MRI contrast agents (314-319) (Fig. 14A) . These constructs consisted of an MMP-2/9 substrate inserted in between a polyanionic peptide and a polycationic cell-penetrating peptide (CPP) conjugated to the imaging probe. The cell-penetrating property of the polycationic peptide was neutralized due to intramolecular electrostatic interactions with the polyanionic domain, preventing cellular uptake of the probe. Cleavage of the substrate by tumoral MMP-2/9 released the polycationic from the polyanionic domain, thereby triggering cellular adhesion and subsequent uptake of the imaging label-functionalized polycationic peptide in tumors. A threefold higher tumor uptake was observed for MMP-2/9 ACPP compared to a scrambled negative control (314) . However, it was recently demonstrated that the tumor targeting of a radiolabeled MMP-2/9 sensitive ACPP is most likely not caused by tumor-specific activation but due to activation of ACPP in the vasculature and subsequent elevated uptake in the tumor due to its enhanced permeability (320, 321) . In this work, dual-isotope radiolabeled ACPPs have been designed that allow in vivo discrimination between uptake of the activated probe and the integral probe ( Fig. 14B ). Most likely, tumor-specific ACPP activation have been limited due to low absolute tumoral MMP activity as a result of local MMP inhibition by the family of tissue inhibitors of metalloproteinases (TIMPs) (321, 322) . In a cardiovascular-disease-related mouse model, a dual-isotope radiolabeled MMP-2/9 sensitive ACPP probe was successfully employed to detect MMP activity in the context of post-ischemic myocardial remodeling (323) ( Fig. 14C  and D) . Furthermore, a ratiometric Cy5/Cy7 labeled MMP-2/9 sensitive ACPP probe allowed the real-time detection of MMP activity in a murine asthma model (324) .
The ACPP imaging concept was further explored for the detection of disease-related enzymes such as urokinase, enterokinase, MMP-14, and plasmin in vitro (314, (325) (326) (327) , as well as acidic conditions, by employing a reduction-sensitive disulfide bridge between the polycationic and polyanionic domain (314) . A novel tumor-homing ACPP, predominantly sensitive for elastases, was identified by a parallel in vitro and in vivo selection with phage displaying a library of ACPPs (328) . Introduction of a NIR quencher at the polyanionic domain led to development of MMP-2 and MMP-7 FRET-based ACPP imaging probes that showed both in vitro activation of fluorescence as well as cellular retention upon cleavage (202, 329) . Furthermore, the similar MMP-2 ACPP probe was succesfully employed in photoacoustic imaging of MMPs in thyroid carcinomas in vivo (203) . Recently, progress was made in the development and application of ratiometric ACPP imaging probes for in vivo detection of thrombin (330, 331) and H 2 O 2 (167) . Finally, it was shown that cellular uptake of ACPP functionalized nanocarriers in vitro, that is, MRI contrast agent functionalized dendrimers (317) or quantum dots (332) , could be modulated by MMP-2. MMP-induced cellular uptake of quantum dots in vitro was also achieved by dePEGylation of CPP functionalized quantum dots (333) .
Recently, a new class of activatable oligomerizable imaging probes has been developed. These probes contain both a N-terminal cysteine residue and a 6-amino-CBT group, in which the former group is protected by a protease-sensitive substrate. Removal of the substrate will liberate the N-terminal D-cysteine residue, allowing an intermolecular condensation reaction between D-cysteine and 6-amino-CBT, yielding a linear oligomer that accumulates. This strategy has been successfully employed to detect intracellular furin by optical and photoacoustic imaging (334, 335) and might be applicable to other intracellular proteases that yield an N-terminal cysteine upon cleavage.
In another approach, cell-internalization was achieved upon activation of a lipid-containing FRET probe (336) . This probe was targeted to the plasma membrane and activation of the probe by MMP-12 resulted in efficient internalization and retention of the donor fluorophore.
Finally, bioresponsive accumulating probes have been developed that need a second target for site-specific retention after its initial activitation. For example, protease-activatable probes have been designed to result in specific retention of the imaging label by tagging of an MMP-2/14 activated transmembrane domain to the cell membrane (337) or specific internalization of an MMP-9 activated probe into scavenger receptor class A type I expressing macrophages (338) . Another example is a fluorescent probe that showed enhanced binding to collagen fibers upon proteolytic activation in vitro (339,340).
CONCLUDING REMARKS
In summary, this review highlights the state-of-the-art of the design and potential application of bioresponsive molecular imaging probes for the monitoring of endogenous targets in vivo. Various strategies of bioresponsive imaging probes have been discussed, varying from protease activatable probes for which the molecular target can continuously activate the imaging probe to a broad spectrum of other endogenous targets for which the imaging label either undergoes a transition from an "off" to an "on" state or is specifically retained at the site of activation. Current and novel bioresponsive molecular imaging probes may play a pivotal role in gathering molecular information underlying biological and cellular processes in basic biology and disease. Therefore, we strongly believe that bioresponsive probes will find various clinical applications, including in (i) diagnostics to improve accurate detection of disease, (ii) intraoperative imaging-guided surgery to improve tumor margin detection, and (iii) real-time assessment of efficacy of therapy/surgery.
